Almotriptan dosage forms and strengths: Difference between revisions

Revision as of 01:57, 5 February 2014

Almotriptan
AXERT^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Almotriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

Tablets: 6.25 mg and 12.5 mg

Revision as of 01:42, 5 February 2014 (view source) Pratik Bahekar (talk \| contribs) (Created page with "__NOTOC__ {{Almotriptan}} {{CMG}}; {{AE}} {{PB}} ==Dosage Forms and Strengths== ==References== {{Reflist\|2}} Category:AntiMigaraineDrugs Category:Drugs")		Revision as of 01:57, 5 February 2014 (view source) Pratik Bahekar (talk \| contribs) No edit summary Newer edit →
Line 5:		Line 5:
	==Dosage Forms and Strengths==		==Dosage Forms and Strengths==

			Tablets: 6.25 mg and 12.5 mg